Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAA50 | Q9GZZ1 | 7/20 | 0.40 |
| ▸ | MMP2 | P08253 | 5/20 | 0.38 |
| ▸ | ANPEP | P15144 | 2/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.36 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10077029 | 0.87 | NAA50 (0.43) | NAA50MMP2ANPEPNR1H2NR1H3 | |
| SCHEMBL10076772 | 0.83 | NR1H2 (0.52) | NAA50NR1H2NR1H3 | |
| SCHEMBL10077136 | 0.83 | NAA50 (0.41) | NAA50MMP2ANPEPNR1H2NR1H3 | |
| SCHEMBL28940964 | 0.83 | NR1H2 (0.39) | NAA50NR1H2NR1H3GPR119UCHL1 | |
| SCHEMBL1275274 | 0.78 | USP30 (0.43) | NR1H2NR1H3GPR119UCHL1USP30 | |
| SCHEMBL1275276 | 0.78 | USP30 (0.43) | NR1H2NR1H3GPR119UCHL1USP30 | |
| SCHEMBL1273270 | 0.76 | NR1H2 (0.40) | NR1H2NR1H3GPR119UCHL1USP30 | |
| SCHEMBL1273394 | 0.76 | NR1H2 (0.40) | NR1H2NR1H3GPR119UCHL1USP30 | |
| SCHEMBL1273147 | 0.76 | NR1H2 (0.40) | NR1H2NR1H3GPR119UCHL1USP30 | |
| SCHEMBL1273532 | 0.74 | NR1H2 (0.41) | NR1H2NR1H3GPR119UCHL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009141-A1 | FUNCTIONALIZED PYRROLIDINES AND USE THEREOF AS IAP INHIBITORS | PHARMASCIENCE INC. (CA) | 2012-01-12 | — | — | US | disclosed |
| WO-2010015090-A1 | FUNCTIONALIZED PYRROLIDINES AND USE THEREOF AS IAP INHIBITORS | AEGERA THERAPEUTICS INC. (CA) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009141-A1 | FUNCTIONALIZED PYRROLIDINES AND USE THEREOF AS IAP INHIBITORS | BIRC5, BIRC7, BIRC2 | NAA50 2589/4885MMP2 381/4885ANPEP 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.